Xenon Pharmaceuticals Inc.'s XEN1101 shows promise in epilepsy with strong phase 2b results and solid financials. Click here ...

Rapport Therapeutics focuses on developing specific small molecule therapies for CNS diseases. Check out my recommendation ...

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset ...

A real-world study supports cenobamate as an effective option for patients with drug-resistant epilepsy even after multiple ...

Childhood epilepsy is more than seizures. Learn to recognize symptoms, manage triggers, and support your child’s well-being.

Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentationMOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

Mayo Clinic is taking epilepsy research in a bold new direction, exploring treatment approaches to help patients living with ...

The moment follows, though was far less pronounced than, an incident in February where he suffered a seizure while delivering ...

The moment follows an incident in February where the congressman suffered a “complex partial seizure” while delivering a ...

NeuroPace gross margin is expected to increase as the margin for SEEG distributed products is approximately 50%, while the margin of the RNS System is over 78%.